Friday, June 26, 2026
← Back to archivePolicy
Policy•STAT News•Jun 25, 2026
New ACIP charter broadens criteria for members, calls for review of alternatives to vaccines
background ▾
- •ACIP charter fundamentally restructured to lower expertise requirements and shift mission away from vaccine recommendations toward assessing disease prevention alternatives, enabling appointment of vaccine skeptics previously deemed unqualified
- •Federal judge previously ruled that most RFK Jr.-appointed committee members failed to meet the original charter's qualification standards, but new charter removes these standards retroactively
- •This represents a significant threat to the integrity of U.S. vaccine policy-making and could materially impact vaccine recommendations, clinical trial assessments, and public health guidance for years to come
Policy•Fierce Biotech•Jun 25, 2026
FDA drops blood pressure device enforcement against Whoop
background ▾
- •FDA reversed enforcement action against Whoop's Blood Pressure Insights feature, classifying it as a general wellness product exempt from medical device regulation rather than a regulated device requiring 510(k) clearance.
- •The decision followed Whoop's proactive labeling and operational modifications that reinforced the wellness purpose of the feature, demonstrating a collaborative regulatory pathway.
- •Watch whether this precedent influences FDA enforcement decisions toward other consumer wearables with clinical-grade sensing capabilities, and whether it signals broader policy softening on general wellness device classification.
WhoopBlood Pressure Insights
→ Read original articlePolicy•STAT News•Jun 26, 2026
Opinion: ‘The Hot Zone’ led me to work with Ebola patients. Now I have mixed feelings about the book
background ▾
- •The 30-year legacy of 'The Hot Zone' continues to drive public panic and misconception about Ebola, portraying it as uniformly hemorrhagic and unstoppable when clinical reality is far more nuanced and treatable through supportive care.
Policy•STAT News•Jun 26, 2026
Jails are the frontline in fielding dangerous new type of drug withdrawal
background ▾
- •Medetomidine withdrawal requires complex treatment with oral and intravenous medications, including ICU-level controlled substances, creating treatment barriers most jails cannot meet
- •Medetomidine is now present across all CDC sentinel surveillance sites, marking a widespread emerging threat in the illicit opioid supply with highest concentration in Northeast regions
- •Allegheny County Jail's collaboration with University of Pittsburgh Medical Center demonstrates that institutional preparedness is possible but depends on resources, political will, and access to addiction medicine expertise—watch for whether other jurisdictions adopt similar models or if federal guidance emerges
medetomidinedexmedetomidinefentanyl
→ Read original articlePolicy•Endpoints News•Jun 25, 2026
Achieve Life Sciences gets a CRL; UPS invests $48M in healthcare logistics
background ▾
- •Achieve Life Sciences' nicotine dependence drug rejected by FDA, requiring substantial additional work before resubmission
- •CRL suggests either efficacy/safety concerns or manufacturing/CMC issues that could delay market entry by 1-2+ years
Achieve Life Sciences
→ Read original articleMarket Access
Market Access•Fierce Biotech•Jun 25, 2026
Fosun Pharma plots global push beyond oncology, fueled by multi-asset Alzheimer’s strategy
background ▾
- •Fosun is betting $260+ million on two Alzheimer's assets to establish itself as a global multinational company and leverage China's growing 17 million Alzheimer's patient population
- •Oligomannate's path forward depends entirely on a redesigned phase 3 trial completion in 2028; success is uncertain given the drug's failed conditional approval renewal and historical data controversies
- •Watch for: Phase 3 trial enrollment and interim data readouts 2026-2028; regulatory outcome of redesigned trial in 2029; AR1001 clinical progress; competitive pressure from Leqembi and Kisunla in oral formulation race
Fosun PharmaGreen Valley PharmaceuticalsAriBiooligomannateGV-971AR1001
→ Read original articleMarket Access•STAT News•Jun 25, 2026
The mysterious case of Eli Lilly’s obesity drug
background ▾
- •Eli Lilly obtained FDA compassionate use authorization for retatrutide in at least one patient, indicating the obesity drug candidate is progressing through development channels
Eli Lillyretatrutide
→ Read original articleMarket Access•Fierce Biotech•Jun 25, 2026
Ionis bags $30M from Recordati for ex-US rights to near-approval rare disease prospect
background ▾
- •Ionis retains U.S. commercial control of zilganersen while Recordati gains ex-U.S. rights, allowing Ionis to capitalize on its first wholly owned neurology launch post-FDA approval
- •The $30 million upfront plus mid-20% royalties reflects modest revenue expectations in a 300-patient U.S. market, though analyst estimates suggest substantially higher peak sales potential ($295M vs. $100M company guidance)
- •FDA approval decision imminent (September 22, 2024); Alexander disease affects only ~300 patients in U.S., making post-approval commercial execution critical to realizing peak sales projections
Ionis PharmaceuticalsRecordatizilganersen
→ Read original articleMarket Access•Endpoints News•Jun 26, 2026
After buying Apellis for $5.6B, Biogen is cutting most of its pipeline work
background ▾
- •Biogen is discontinuing most of Apellis's pipeline programs post-acquisition, indicating a significant portfolio rationalization rather than a full integration strategy
- •The $5.6B acquisition appears to be narrowing in scope to select assets, raising concerns among investors about deal value realization and capital allocation efficiency
- •Biogen workforce reductions signal cost restructuring; clarity needed on which Apellis programs remain active and their commercial timelines
BiogenApellis Pharmaceuticals
→ Read original articleMarket Access•Fierce Biotech•Jun 25, 2026
With $15M discovery deal, Boehringer becomes latest Big Pharma to buy into Immunai’s AI platform
background ▾
- •Immunai has now secured partnerships with three tier-one pharmas in 2024 ($15M Boehringer, $37.5M AstraZeneca expansion, plus Bristol Myers Squibb), signaling market confidence in integrated AI + wet lab discovery models over software-only approaches
- •The deal targets a therapeutically adjacent space (cancer immunology and autoimmune T-cell dysfunction) that Immunai claims has been historically explored in silos, offering potential for cross-disease target discovery insights
- •Monitor whether target identification leads to actual IND-enabling candidates and whether the optional deal expansion materializes—success will validate whether pharma-AI partnerships can materially accelerate discovery timelines
Boehringer IngelheimImmunaiBristol Myers Squibb
→ Read original articleClinical Trials
Clinical Trials•Fierce Biotech•Jun 25, 2026
Otsuka posts phase 3b ADHD trial win ahead of looming FDA approval decision
background ▾
- •Phase 3b trial met primary endpoint in the clinically important ADHD+anxiety comorbidity population (1/3 of ADHD cases), with larger placebo-adjusted separation than earlier phase 3 trials restricted to non-anxious patients
- •Centanafadine demonstrated statistically significant anxiety improvement (HAM-A), potentially broadening the addressable market beyond standard ADHD populations
- •FDA decision imminent (July 24); watch for approval timing and whether DEA scheduling requirement materializes, as this could delay commercial launch by 3 months despite already-mobilized sales infrastructure
Otsukacentanafadine
→ Read original articleClinical Trials•Fierce Biotech•Jun 26, 2026
How iBio aims to stand out in obesity by targeting ‘both sides of the equation’ for antibody discovery
background ▾
- •iBio's AI platform uniquely optimizes 'both sides' of the antibody-antigen equation—simultaneously engineering difficult-to-target epitopes and screening antibodies through parallel in silico and human library approaches
- •Lead candidate IBO-610 targets Activin E for weight loss with engineered extended half-life to address adherence challenges post-GLP-1 discontinuation, positioning it as a potential bridge therapy
- •Watch for IBO-610 clinical trial initiation and early efficacy data; iBio's credibility hinges on rapid clinical validation given its recent strategic pivot and the crowded competitive landscape
iBioRubrYc TherapeuticsMedicagoIBO-610
→ Read original articleClinical Trials•STAT News•Jun 26, 2026
What is pulmonary hypertension and why would a new GLP-1 help?
background ▾
- •GLP-1s may have therapeutic potential in pulmonary hypertension secondary to HFpEF and obesity-related PH, but clinical evidence is preliminary and largely observational
- •Pulmonary hypertension is a heterogeneous disease with multiple etiologies; benefit would likely depend on underlying cause and may not be universal across PH subtypes
- •Watch for prospective clinical trial initiation specifically testing GLP-1 agents in pulmonary hypertension populations; early studies (Vanderbilt preprint, literature reviews) suggest the hypothesis warrants formal investigation
Eli Lillyretatrutide
→ Read original articleClinical Trials•STAT News•Jun 26, 2026
Opinion: Joseph Fraumeni Jr., pioneering cancer genetics researcher, devoted his life to families like mine
background ▾
- •Joseph Fraumeni Jr. and Frederick Pei Li's 1969 hypothesis and subsequent validation of Li-Fraumeni syndrome established the field of hereditary cancer research, fundamentally shifting understanding of cancer etiology from purely sporadic to familial/genetic
Clinical Trials•Fierce Biotech•Jun 25, 2026
BIO 2026: How a gut feeling transformed cancer treatment forever
background ▾
- •This is largely a retrospective commentary on immunotherapy's transformation from fringe science to standard care; no new trial results, approvals, or policy changes are reported
RegeneronMerckBristol Myers SquibbKeytrudaOpdivoKymriah
→ Read original article